Skip to main content

Table 1 J10 and J27-related disease criteria on all patients

From: Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data

% Disease State* Baseline
N=178
D15
N=172
D29
N=157
D57
N=131
D85
N=125
J10 ID 0.0 18.0 26.8 34.4 33.6
  LDA 0.0 14.0 11.5 16.8 24.8
  MDA 0.6 19.2 19.7 20.6 16.8
  HDA 99.4 48.8 42.0 28.2 24.8
J27 ID 0.0 18.0 26.8 34.4 33.6
  LDA 0.0 14.0 11.5 16.8 25.6
  MDA 0.6 15.1 16.6 17.6 12.8
  HDA 99.4 52.9 45.2 31.3 28.0
  1. *Cut-off values for ID, LDA, MDA and HDA, respectively for J10: ≤1, >1-≤3.8, >3.8 - ≤10.5, >10.5; and for J27: ≤1, >1 - ≤3.8, >3.8 - ≤8.5, >8.5